Literature DB >> 19109256

A new isoform of interleukin-3 receptor {alpha} with novel differentiation activity and high affinity binding mode.

Jinglong Chen1, Jane Olsen, Sally Ford, Shamaruh Mirza, Andrew Walker, James M Murphy, Ian G Young.   

Abstract

Interleukin-3 (IL-3) promotes both self-renewal and differentiation of early multipotential progenitors and is involved in inducible hematopoiesis in response to infections. Here we report new insights into these processes with the identification of a new isoform (SP2) of IL-3 receptor alpha (IL-3Ralpha), present in mouse and human hematopoietic cells, which lacks domain 1 of the full-length receptor (SP1). Binding assays with beta(IL-3) mutants showed that mouse SP2 uses a different high affinity binding mode to SP1, although both mouse and human SP2 and SP1 can stimulate IL-3-dependent growth. In IL-3-dependent differentiation models, human SP2 and SP1 gave differential effects on lineage commitment or self-renewal dependent on the cellular context, suggesting that different modes of ectodomain binding may modulate intracellular signaling. In a multipotential factor dependent cell-Paterson mix, the transcription factors C/EBPalpha and PU.1 and microRNAs miRNA-15a, -223, and -181a were up-regulated in cells undergoing SP2-supported differentiation compared with SP1-supported self-renewal. Similarly in M1 cells, SP2 promoted differentiation compared with SP1 and gave up-regulation of PU.1 and miRNA-155 and -223. These findings suggest that IL-3-promoted lineage commitment uses similar mechanisms to those of steady-state hematopoiesis. Both the SP1 and SP2 isoforms activated the Jak2/STAT5, Akt, and Erk1/2 signaling pathways in M1 cells, although the activation was more prolonged for the SP2 isoform.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109256     DOI: 10.1074/jbc.M808197200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Two modes of beta-receptor recognition are mediated by distinct epitopes on mouse and human interleukin-3.

Authors:  Shamaruh Mirza; Jinglong Chen; Bin Wen; Cameron L Ewens; Jin Dai; James M Murphy; Ian G Young
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

Review 2.  Cytokine receptor splice variants in hematologic diseases.

Authors:  Borwyn Wang; Hrishikesh Mehta
Journal:  Cytokine       Date:  2019-12-06       Impact factor: 3.861

3.  A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.

Authors:  Yelena Kovtun; Gregory E Jones; Sharlene Adams; Lauren Harvey; Charlene A Audette; Alan Wilhelm; Chen Bai; Lingyun Rui; Rassol Laleau; Fenghua Liu; Olga Ab; Yulius Setiady; Nicholas C Yoder; Victor S Goldmacher; Ravi V J Chari; Jan Pinkas; Thomas Chittenden
Journal:  Blood Adv       Date:  2018-04-24

4.  The role of interchain heterodisulfide formation in activation of the human common beta and mouse betaIL-3 receptors.

Authors:  Shamaruh Mirza; Jinglong Chen; James M Murphy; Ian G Young
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

5.  CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Authors:  Adam J Lamble; Lisa Eidenschink Brodersen; Todd A Alonzo; Jim Wang; Laura Pardo; Lillian Sung; Todd M Cooper; E Anders Kolb; Richard Aplenc; Sarah K Tasian; Michael R Loken; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2021-12-02       Impact factor: 44.544

Review 6.  The potential for genetically altered microglia to influence glioma treatment.

Authors:  W Li; R M D Holsinger; C A Kruse; A Flügel; M B Graeber
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-09       Impact factor: 4.388

Review 7.  The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease.

Authors:  Timothy R Hercus; Daniel Thomas; Mark A Guthridge; Paul G Ekert; Jack King-Scott; Michael W Parker; Angel F Lopez
Journal:  Blood       Date:  2009-05-12       Impact factor: 22.113

8.  High yield production of a soluble human interleukin-3 variant from E. coli with wild-type bioactivity and improved radiolabeling properties.

Authors:  Timothy R Hercus; Emma F Barry; Mara Dottore; Barbara J McClure; Andrew I Webb; Angel F Lopez; Ian G Young; James M Murphy
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

9.  Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles.

Authors:  Seema Singh; Rakesh Verma; Anamika Pradeep; Karen Leu; R Bruce Mortensen; Peter R Young; Miho Oyasu; Peter J Schatz; Jennifer M Green; Don M Wojchowski
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

Review 10.  Current Concept and Update of the Macrophage Plasticity Concept: Intracellular Mechanisms of Reprogramming and M3 Macrophage "Switch" Phenotype.

Authors:  Igor Malyshev; Yuri Malyshev
Journal:  Biomed Res Int       Date:  2015-08-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.